In Medicare Drug Price Negotiations, Industry Sees Drawbacks And Silver Linings
Drug Pricing Changes Were Top Of Mind At J.P. Morgan
Industry leaders are concerned about the outlook for small molecule drugs in particular, but execs at the J.P. Morgan Healthcare Conference were also optimistic there could be chances to shape the implementation of certain policies.
You may also be interested in...
Pharma leaders and stakeholders discussed industry priorities related to the implementation of the Inflation Reduction Act during the BIO CEO and Investor Conference.
Medicare Price Negotiation: Sponsors Will Have A Say, But Likely Not Sway As Timetable Comes Into Focus
CMS details when it will release information and receive public comments in the lead-up to publishing the initial list of drugs to be negotiated this fall.
Alnylam decision has been seized by opponents of Medicare price negotiation as evidence the nascent program will undermine innovation, particularly for small molecule drugs.